We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

KBC:EURONEXT BRUSSELSKBC Group N.V. Analysis

Data as of 2026-06-06 - not real-time

SEK 42.10

Latest Price

8/10Risk

Risk Level: High

Executive Summary

KB Components trades around SEK 42.1, sitting just below its 20‑day SMA of roughly SEK 44 but marginally above the 50‑day and 200‑day SMAs (≈ SEK 42.9 and SEK 42.96). The RSI of 46 indicates a neutral momentum environment, while the MACD histogram remains negative, signalling bearish short‑term pressure. The stock faces a clear technical support near SEK 37 and a resistance ceiling around SEK 47.5, with volatility spiking above 70% on a 30‑day basis and a beta of –0.78 suggesting an inverse reaction to broader market moves. Fundamentally, revenue has slipped 12.5% YoY, margins are thin (gross margin ~51%, operating margin ~6%), and the company carries a heavy debt load (debt‑to‑equity >200%). The PE ratio sits at 33.7, well above the sector average, while the forward PE of roughly 12 is skewed by a zero forward EPS estimate. Dividend yield appears attractive at 3.6%, but a payout ratio exceeding 120% raises sustainability concerns. Overall, the blend of a deteriorating earnings profile, high valuation multiples, and elevated technical risk suggests caution, with the stock positioned in a narrow range that could be tested either side of its current level.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • Bearish MACD and price below short‑term SMA
  • High 30‑day volatility and negative beta
  • Approaching technical support at SEK 37

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Continued revenue decline and thin margins
  • Elevated debt‑to‑equity ratio limiting flexibility
  • Dividend yield offset by unsustainable payout

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Structural demand for polymer components in automotive and medical sectors
  • Potential for balance‑sheet deleveraging over time
  • Valuation still above intrinsic benchmarks despite growth constraints

Key Metrics & Analysis

Financial Health

Revenue Growth-12.50%
Profit Margin2.60%
P/E Ratio33.7
ROE10.97%
ROA4.00%
Debt/Equity202.41
P/B Ratio4.0
Op. Cash FlowSEK282.7M
Free Cash FlowSEK37.3M

Technical Analysis

TrendNeutral
RSI46.1
SupportSEK 37.00
ResistanceSEK 47.50
MA 20SEK 44.00
MA 50SEK 42.88
MA 200SEK 42.96
MACDBearish
VolumeStable
Fear & Greed Index83.02

Valuation

Target PriceSEK 47.00
Upside/Downside11.64%
GradeOvervalued
TypeValue
Dividend Yield3.56%

Risk Assessment

Beta-0.78
Volatility73.32%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.